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Abstract 
Substance use disorders (SUD) and Attention deficit /hyperactivity disorder (ADHD) are persistent and 
prevailing disorders that conjointly are associated with negative life-events and mental distress. The overall aim 
of this thesis was to examine the rate of ADHD in substance using populations and to investigate the feasibility 
and efficacy of methylphenidate pharmacotherapy for treatment of co-existing ADHD and SUD. 
The prevalence of ADHD was investigated in Studies I and II, which were cross-sectional 
investigations including two stages: screening and assessment. Study I included seven countries; France, 
Hungary, the Netherlands, Norway, Spain, Sweden, and Switzerland. Study II comprised incarcerated women in 
Swedish prisons. An initial screening was completed with WHO’s Adult ADHD Self-Rating Scale (ASRS). The 
assessment included Conners’ Adult ADHD interview for DSM-IV (CAADID) as a ‘gold standard’ for ADHD 
diagnosis. For differential diagnostics, the MINI Plus interview was used for mood disorders, antisocial 
personality disorder (ASP) and SUD, and SCID-II was used to assess borderline personality disorder (BPD). 
The results show that compared to the general population, the rate of ADHD is higher both in treatment-seeking 
substance users and in female prisoners (Study I and II). 
Studies III and IV were randomized, double-blind, placebo-controlled trials with parallel groups 
design investigating the safety and efficacy of methylphenidate (MPH) for treatment of ADHD in amphetamine 
dependent patients. Study III was a 12-week trial investigating 18-72mg/day MPH in treatment-seeking 
outpatients (men and women) with change in ADHD symptoms as the primary outcome measure. Study IV was 
a 24-week trial investigating 18-180 mg/day MPH in men recruited from medium security prisons. The 
participants started treatment within two weeks before release from prison and continued treatment in an 
outpatient clinic. The primary outcome measure in Study IV was relapse to illicit drug use. Results from Study 
III show that both treatment groups significantly improved their ADHD symptoms, but there were no significant 
differences between the groups in either ADHD or substance use outcome measures. In study IV, compared to 
placebo treatment, MPH treatment resulted in significantly more negative urine samples, improvement in 
ADHD symptoms, and better retention in treatment. 
 Collectively, the findings from the epidemiological studies suggest that a significant number of 
individuals with SUD are also afflicted with ADHD. It is important that more attention is given to adult ADHD 
in addiction treatment centres and in criminal justice systems in order to address the clinical needs of this 
population. The results from the present clinical trials suggest that MPH given in structured settings may be safe 
to use in currently abstinent amphetamine dependent individuals with ADHD. A flexible dose range with a 
higher maximum dose improved ADHD symptoms, clinical condition and retention in treatment, and reduced 
the risk for relapse to illicit drug use in long-term drug dependent individuals. 
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